FDA Approves Anumana Pulmonary Hypertension Algorithm
Anumana has obtained 510(okay) clearance from the US Meals and Drug Administration (FDA) for its ECG-AI pulmonary hypertension (PH) detection algorithm, a software-as-a-medical-device (SaMD).
The algorithm is designed to establish early indicators of PH utilizing customary 12-lead electrocardiograms (ECGs). It’s now accessible in a variety of healthcare settings.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra info
PH is a progressive pulmonary vascular illness and impacts an estimated 1% of the world’s inhabitants.
Anumana’s PH algorithm identifies delicate abnormalities in ECGs and helps clinicians in deciding when to pursue follow-up diagnostics, akin to echocardiography, inside present scientific workflows.
It integrates straight with digital well being report (EHR) programs and ECG administration platforms, and capabilities fully throughout the healthcare system surroundings with out exterior switch of affected person knowledge.
Anumana COO and President Simos Kedikoglou mentioned: “The FDA approval of our PH algorithm is the results of rigorous scientific growth and regulatory work, and it marks a significant step towards increasing entry to AI-enabled insights on the level of care.
“As a result of the primary PH algorithm is accredited to be used with customary 12-lead ECGs, it’s extensively accessible throughout all healthcare settings, integrates straight into current scientific workflows, and helps scientific resolution making in actual time, with the potential to assist establish sufferers earlier of their illness course. This milestone displays Anumana’s broader imaginative and prescient to increase the position of ECGs in figuring out cardiovascular threat earlier and at scale.”
The algorithm was developed utilizing knowledge from greater than 250,000 anonymized affected person information from the Mayo Clinic and was validated in a multicenter research of 21,066 sufferers throughout 5 U.S. healthcare programs. On this research, the ECG-AI detected PH with a sensitivity of 73% and a specificity of 74.4% in adults with dyspnea.
Mayo Clinic, co-founder of Anumana, has a monetary stake within the firm.
In January 2025, Anumana partnered with AliveCor to develop its AI algorithms meant for the early identification of coronary heart illnesses.
